In May 2009, NICE published recommendations on the use of newer agents for the control of blood glucose in type 2 diabetes. This guideline provides a partial update for NICE Clinical Guideline 66 on the management of type 2 diabetes that was published last year. These newer agents include the dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), the glucagon-like peptide-1 (GLP-1) mimetic exenatide and the long-acting insulin analogues (insulin detemir and insulin glargine).
What can cardiac CT imaging add to our understanding in primary care?
The art of knowing when to take action and when to let well alone
Reply to Primary Care View on advances in cardiac tomography
Advances in cardiac computed tomography: an update for primary care physicians
When to use aspirin in the primary and secondary prevention of cardiovascular disease: acting on the latest evidence
Chronic kidney disease, estimated glomerular filtration rate and the Quality and Outcomes Framework: a survey of GPs in the UK
International expert committee recommends new role for HbA1C in diagnosing diabetes
A commentary on the NICE guideline on identification and management of familial hypercholesterolaemia
Making sense of triglycerides
Antibiotic prophylaxis against infective endocarditis
Navigating the new NICE guideline on type 2 diabetes: Finding the best treatment pathway for each patient
The new NICE guideline enables us to individualise care bearing in mind the needs of the person in front of us. It is concerned with clinical efficacy, and – for once – the cost of care has not noticeably influenced its recommendations. In contrast, QOF does the exact opposite, demanding that we drive our patients’ HbA1c down to low […]
